Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C (Q33800611)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C |
scientific article |
Statements
1 reference
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C (English)
1 reference
D Sargent
1 reference
Q Shi
1 reference
G Yothers
1 reference
E Van Cutsem
1 reference
J Cassidy
1 reference
L Saltz
1 reference
N Wolmark
1 reference
B Bot
1 reference
A Grothey
1 reference
M Buyse
1 reference
A de Gramont
1 reference
Adjuvant Colon Cancer End-points (ACCENT) Group
1 reference
21 January 2011
1 reference
1 reference
47
1 reference
990-996
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference